Anti-VEGF Drugs Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application, Product Type
By: HDIN Research
Published: 2025-09-21
Pages: 127
Market Research Report Price
- Single User License (1 Users) $ 3,600
- Team License (2~5 Users) $ 4,600
- Corporate License (>5 Users) $ 5,600
Anti-VEGF Drugs Market Summary
The anti-vascular endothelial growth factor (anti-VEGF) drugs market is a critical segment of the pharmaceutical industry, providing therapies for conditions characterized by abnormal blood vessel growth, such as certain cancers and eye diseases. Anti-VEGF drugs target VEGF, a protein that promotes angiogenesis, to inhibit tumor growth in cancers like colorectal and lung cancer, and to manage retinal disorders like age-related macular degeneration (AMD) and diabetic retinopathy. The market is characterized by high innovation, significant R&D investment, and a shift toward biosimilars as patents for blockbuster drugs expire. By 2025, the global anti-VEGF drugs market is estimated to be valued between USD 15 billion and USD 25 billion, with a projected compound annual growth rate (CAGR) of 2.1% to 4.1% through 2030. Growth is driven by rising disease prevalence, aging populations, and biosimilar adoption, tempered by patent expirations and pricing pressures. Anti-VEGF drugs include monoclonal antibodies (e.g., bevacizumab, ranibizumab), fusion proteins (e.g., aflibercept), and small molecules (e.g., sunitinib, sorafenib), each designed to inhibit VEGF activity. These drugs are critical for treating cancers and eye diseases, offering targeted therapies with significant clinical benefits. The industry is shaped by the high cost of biologics, complex manufacturing processes, and the emergence of biosimilars following patent expirations for drugs like Roche’s Avastin (bevacizumab) and Bayer/Regeneron’s Eylea (aflibercept). The market is also influenced by advancements in drug delivery, such as ocular implants, and the growing adoption of combination therapies to enhance efficacy. Regulatory approvals, reimbursement policies, and competition from biosimilars are key factors shaping market dynamics.
Regional Market Trends
The anti-VEGF drugs market varies across regions, driven by healthcare infrastructure, disease prevalence, and biosimilar adoption.
● North America: The United States leads with a CAGR of 1.5%–3.5%, driven by high demand for eye disease treatments and oncology therapies. The region benefits from advanced healthcare systems but faces challenges from biosimilar competition.
● Europe: Germany, France, and the United Kingdom are key markets, with a CAGR of 1.8%–3.8%. Growth is supported by aging populations and robust reimbursement systems, though pricing pressures and biosimilar penetration limit expansion.
● Asia-Pacific: Japan and China drive growth with a CAGR of 3.0%–5.0%. Japan’s advanced healthcare system supports premium anti-VEGF drugs, while China’s expanding oncology and ophthalmology markets boost demand. India is emerging due to increasing biosimilar adoption.
● Latin America: Brazil and Mexico have a CAGR of 2.0%–4.0%, driven by improving healthcare access and rising cancer prevalence. Biosimilars offer cost-effective options, supporting market growth.
● Middle East and Africa (MEA): The region, including Saudi Arabia and South Africa, has a CAGR of 2.5%–4.5%. Growth is supported by increasing healthcare investments, but limited access to biologics constrains potential.
Application and Type Analysis
The anti-VEGF drugs market is segmented by application and type, each with distinct growth trends.
● Cancer Treatment: This application, including colorectal, lung, and renal cancers. Drugs like bevacizumab and sunitinib are widely used, but biosimilar competition is increasing as patents expire.
● Eye Disease Treatment: This segment, covering AMD, diabetic retinopathy, and retinal vein occlusion. Drugs like aflibercept and ranibizumab dominate, with innovations like faricimab and ocular implants driving growth.
● Aflibercept: Marketed as Eylea by Bayer/Regeneron. Patent expirations in 2025 will drive biosimilar competition, though demand remains strong for eye diseases.
● Bevacizumab: Sold as Avastin by Roche. Patent expiration has led to biosimilar growth, particularly in oncology.
● Ranibizumab: Marketed as Lucentis by Roche/Novartis, Biosimilars like Byooviz and Cimerli are gaining traction.
● Faricimab: Launched as Vabysmo by Roche in 2022, driven by its dual-target mechanism for eye diseases.
● Sunitinib and Sorafenib: These small molecules, sold as Sutent (Pfizer) and Nexavar (Bayer) used primarily in oncology.
● Others: Including biosimilars and emerging therapies, driven by cost-effective alternatives.
Company Profiles
● Bayer: Markets Eylea (aflibercept) outside the U.S. and Nexavar (sorafenib), generating USD 3–4 billion from Eylea in 2024. Faces biosimilar competition post-2025 patent expiration.
● Regeneron Pharmaceuticals: Leads with Eylea and Eylea HD in the U.S., with USD 9–10 billion in 2024 revenue. Focuses on innovation in eye disease treatments.
● Roche: Through Genentech, Roche markets Avastin (bevacizumab), Lucentis (ranibizumab), and Vabysmo (faricimab), with combined 2024 revenues of USD 3–5 billion. Its innovation pipeline supports growth.
● Pfizer: Markets Sutent (sunitinib) and supports oncology applications, with a strong global commercial presence.
● Amgen: Launched Pavblu (aflibercept biosimilar) in Q4 2024, targeting cost-effective eye disease treatments.
● Novartis: Markets Lucentis outside the U.S. and Beovu (brolucizumab), focusing on ophthalmology.
● Samsung Bioepis and Biogen: Offer Byooviz (ranibizumab biosimilar), expanding access in cost-sensitive markets.
Industry Value Chain Analysis
The anti-VEGF drugs value chain begins with R&D, involving drug discovery, clinical trials, and regulatory approvals to develop biologics and small molecules. Manufacturing requires advanced bioprocessing for biologics and chemical synthesis for small molecules, adhering to strict quality standards. Distribution involves global supply chains, with companies partnering with wholesalers and specialty pharmacies to reach hospitals and clinics. Marketing targets healthcare providers, emphasizing clinical efficacy and patient outcomes.
Healthcare providers administer anti-VEGF drugs to patients via injections or oral formulations, supported by reimbursement systems. Pharmacovigilance ensures ongoing safety monitoring. The value chain is complex, with high costs for biologics offset by economies of scale for biosimilars, which are gaining traction in cost-sensitive markets.
Opportunities and Challenges
Opportunities:
● Aging Population: Rising prevalence of AMD and cancer drives demand for anti-VEGF therapies.
● Biosimilar Growth: Patent expirations create opportunities for cost-effective biosimilars, particularly in emerging markets.
● Innovative Therapies: New drugs like faricimab and delivery systems like ocular implants enhance treatment outcomes.
● Emerging Markets: Expanding healthcare access in Asia-Pacific and Latin America boosts demand.
Challenges:
● Patent Expirations: Expirations for drugs like Eylea and Lucentis increase biosimilar competition, pressuring revenues.
● High Costs: The high cost of biologics limits access in low-income regions, despite biosimilar availability.
● Regulatory Barriers: Stringent approval processes for biosimilars and new drugs increase development costs.
● Competition from Alternatives: Emerging therapies, such as gene therapies for eye diseases, may challenge anti-VEGF market share.
The anti-vascular endothelial growth factor (anti-VEGF) drugs market is a critical segment of the pharmaceutical industry, providing therapies for conditions characterized by abnormal blood vessel growth, such as certain cancers and eye diseases. Anti-VEGF drugs target VEGF, a protein that promotes angiogenesis, to inhibit tumor growth in cancers like colorectal and lung cancer, and to manage retinal disorders like age-related macular degeneration (AMD) and diabetic retinopathy. The market is characterized by high innovation, significant R&D investment, and a shift toward biosimilars as patents for blockbuster drugs expire. By 2025, the global anti-VEGF drugs market is estimated to be valued between USD 15 billion and USD 25 billion, with a projected compound annual growth rate (CAGR) of 2.1% to 4.1% through 2030. Growth is driven by rising disease prevalence, aging populations, and biosimilar adoption, tempered by patent expirations and pricing pressures. Anti-VEGF drugs include monoclonal antibodies (e.g., bevacizumab, ranibizumab), fusion proteins (e.g., aflibercept), and small molecules (e.g., sunitinib, sorafenib), each designed to inhibit VEGF activity. These drugs are critical for treating cancers and eye diseases, offering targeted therapies with significant clinical benefits. The industry is shaped by the high cost of biologics, complex manufacturing processes, and the emergence of biosimilars following patent expirations for drugs like Roche’s Avastin (bevacizumab) and Bayer/Regeneron’s Eylea (aflibercept). The market is also influenced by advancements in drug delivery, such as ocular implants, and the growing adoption of combination therapies to enhance efficacy. Regulatory approvals, reimbursement policies, and competition from biosimilars are key factors shaping market dynamics.
Regional Market Trends
The anti-VEGF drugs market varies across regions, driven by healthcare infrastructure, disease prevalence, and biosimilar adoption.
● North America: The United States leads with a CAGR of 1.5%–3.5%, driven by high demand for eye disease treatments and oncology therapies. The region benefits from advanced healthcare systems but faces challenges from biosimilar competition.
● Europe: Germany, France, and the United Kingdom are key markets, with a CAGR of 1.8%–3.8%. Growth is supported by aging populations and robust reimbursement systems, though pricing pressures and biosimilar penetration limit expansion.
● Asia-Pacific: Japan and China drive growth with a CAGR of 3.0%–5.0%. Japan’s advanced healthcare system supports premium anti-VEGF drugs, while China’s expanding oncology and ophthalmology markets boost demand. India is emerging due to increasing biosimilar adoption.
● Latin America: Brazil and Mexico have a CAGR of 2.0%–4.0%, driven by improving healthcare access and rising cancer prevalence. Biosimilars offer cost-effective options, supporting market growth.
● Middle East and Africa (MEA): The region, including Saudi Arabia and South Africa, has a CAGR of 2.5%–4.5%. Growth is supported by increasing healthcare investments, but limited access to biologics constrains potential.
Application and Type Analysis
The anti-VEGF drugs market is segmented by application and type, each with distinct growth trends.
● Cancer Treatment: This application, including colorectal, lung, and renal cancers. Drugs like bevacizumab and sunitinib are widely used, but biosimilar competition is increasing as patents expire.
● Eye Disease Treatment: This segment, covering AMD, diabetic retinopathy, and retinal vein occlusion. Drugs like aflibercept and ranibizumab dominate, with innovations like faricimab and ocular implants driving growth.
● Aflibercept: Marketed as Eylea by Bayer/Regeneron. Patent expirations in 2025 will drive biosimilar competition, though demand remains strong for eye diseases.
● Bevacizumab: Sold as Avastin by Roche. Patent expiration has led to biosimilar growth, particularly in oncology.
● Ranibizumab: Marketed as Lucentis by Roche/Novartis, Biosimilars like Byooviz and Cimerli are gaining traction.
● Faricimab: Launched as Vabysmo by Roche in 2022, driven by its dual-target mechanism for eye diseases.
● Sunitinib and Sorafenib: These small molecules, sold as Sutent (Pfizer) and Nexavar (Bayer) used primarily in oncology.
● Others: Including biosimilars and emerging therapies, driven by cost-effective alternatives.
Company Profiles
● Bayer: Markets Eylea (aflibercept) outside the U.S. and Nexavar (sorafenib), generating USD 3–4 billion from Eylea in 2024. Faces biosimilar competition post-2025 patent expiration.
● Regeneron Pharmaceuticals: Leads with Eylea and Eylea HD in the U.S., with USD 9–10 billion in 2024 revenue. Focuses on innovation in eye disease treatments.
● Roche: Through Genentech, Roche markets Avastin (bevacizumab), Lucentis (ranibizumab), and Vabysmo (faricimab), with combined 2024 revenues of USD 3–5 billion. Its innovation pipeline supports growth.
● Pfizer: Markets Sutent (sunitinib) and supports oncology applications, with a strong global commercial presence.
● Amgen: Launched Pavblu (aflibercept biosimilar) in Q4 2024, targeting cost-effective eye disease treatments.
● Novartis: Markets Lucentis outside the U.S. and Beovu (brolucizumab), focusing on ophthalmology.
● Samsung Bioepis and Biogen: Offer Byooviz (ranibizumab biosimilar), expanding access in cost-sensitive markets.
Industry Value Chain Analysis
The anti-VEGF drugs value chain begins with R&D, involving drug discovery, clinical trials, and regulatory approvals to develop biologics and small molecules. Manufacturing requires advanced bioprocessing for biologics and chemical synthesis for small molecules, adhering to strict quality standards. Distribution involves global supply chains, with companies partnering with wholesalers and specialty pharmacies to reach hospitals and clinics. Marketing targets healthcare providers, emphasizing clinical efficacy and patient outcomes.
Healthcare providers administer anti-VEGF drugs to patients via injections or oral formulations, supported by reimbursement systems. Pharmacovigilance ensures ongoing safety monitoring. The value chain is complex, with high costs for biologics offset by economies of scale for biosimilars, which are gaining traction in cost-sensitive markets.
Opportunities and Challenges
Opportunities:
● Aging Population: Rising prevalence of AMD and cancer drives demand for anti-VEGF therapies.
● Biosimilar Growth: Patent expirations create opportunities for cost-effective biosimilars, particularly in emerging markets.
● Innovative Therapies: New drugs like faricimab and delivery systems like ocular implants enhance treatment outcomes.
● Emerging Markets: Expanding healthcare access in Asia-Pacific and Latin America boosts demand.
Challenges:
● Patent Expirations: Expirations for drugs like Eylea and Lucentis increase biosimilar competition, pressuring revenues.
● High Costs: The high cost of biologics limits access in low-income regions, despite biosimilar availability.
● Regulatory Barriers: Stringent approval processes for biosimilars and new drugs increase development costs.
● Competition from Alternatives: Emerging therapies, such as gene therapies for eye diseases, may challenge anti-VEGF market share.
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Abbreviation and Acronyms
Chapter 3 Preface
3.1 Research Scope
3.2 Research Sources
3.2.1 Data Sources
3.2.2 Assumptions
3.3 Research Method
Chapter 4 Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users
Chapter 5 Market Trend Analysis
5.1 introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
Chapter 6 industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 Anti-VEGF Drugs Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users
Chapter 7 Latest Market Dynamics
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
Chapter 8 Historical and Forecast Anti-VEGF Drugs Market in North America (2020-2030)
8.1 Anti-VEGF Drugs Market Size
8.2 Anti-VEGF Drugs Market by End Use
8.3 Competition by Players/Suppliers
8.4 Anti-VEGF Drugs Market Size by Type
8.5 Key Countries Analysis
8.5.1 United States
8.5.2 Canada
8.5.3 Mexico
Chapter 9 Historical and Forecast Anti-VEGF Drugs Market in South America (2020-2030)
9.1 Anti-VEGF Drugs Market Size
9.2 Anti-VEGF Drugs Market by End Use
9.3 Competition by Players/Suppliers
9.4 Anti-VEGF Drugs Market Size by Type
9.5 Key Countries Analysis
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Chile
9.5.4 Peru
Chapter 10 Historical and Forecast Anti-VEGF Drugs Market in Asia & Pacific (2020-2030)
10.1 Anti-VEGF Drugs Market Size
10.2 Anti-VEGF Drugs Market by End Use
10.3 Competition by Players/Suppliers
10.4 Anti-VEGF Drugs Market Size by Type
10.5 Key Countries Analysis
10.5.1 China
10.5.2 India
10.5.3 Japan
10.5.4 South Korea
10.5.5 Southest Asia
10.5.6 Australia
Chapter 11 Historical and Forecast Anti-VEGF Drugs Market in Europe (2020-2030)
11.1 Anti-VEGF Drugs Market Size
11.2 Anti-VEGF Drugs Market by End Use
11.3 Competition by Players/Suppliers
11.4 Anti-VEGF Drugs Market Size by Type
11.5 Key Countries Analysis
11.5.1 Germany
11.5.2 France
11.5.3 United Kingdom
11.5.4 Italy
11.5.5 Spain
11.5.6 Belgium
11.5.7 Netherlands
11.5.8 Austria
11.5.9 Poland
11.5.10 Russia
Chapter 12 Historical and Forecast Anti-VEGF Drugs Market in MEA (2020-2030)
12.1 Anti-VEGF Drugs Market Size
12.2 Anti-VEGF Drugs Market by End Use
12.3 Competition by Players/Suppliers
12.4 Anti-VEGF Drugs Market Size by Type
12.5 Key Countries Analysis
12.5.1 Egypt
12.5.2 Israel
12.5.3 South Africa
12.5.4 Gulf Cooperation Council Countries
12.5.5 Turkey
Chapter 13 Summary For Global Anti-VEGF Drugs Market (2020-2025)
13.1 Anti-VEGF Drugs Market Size
13.2 Anti-VEGF Drugs Market by End Use
13.3 Competition by Players/Suppliers
13.4 Anti-VEGF Drugs Market Size by Type
Chapter 14 Global Anti-VEGF Drugs Market Forecast (2025-2030)
14.1 Anti-VEGF Drugs Market Size Forecast
14.2 Anti-VEGF Drugs Application Forecast
14.3 Competition by Players/Suppliers
14.4 Anti-VEGF Drugs Type Forecast
Chapter 15 Analysis of Global Key Vendors
15.1 Bayer
15.1.1 Company Profile
15.1.2 Main Business and Anti-VEGF Drugs Information
15.1.3 SWOT Analysis of Bayer
15.1.4 Bayer Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.2 Regeneron Pharmaceuticals
15.2.1 Company Profile
15.2.2 Main Business and Anti-VEGF Drugs Information
15.2.3 SWOT Analysis of Regeneron Pharmaceuticals
15.2.4 Regeneron Pharmaceuticals Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.3 Roche
15.3.1 Company Profile
15.3.2 Main Business and Anti-VEGF Drugs Information
15.3.3 SWOT Analysis of Roche
15.3.4 Roche Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.4 Pfizer
15.4.1 Company Profile
15.4.2 Main Business and Anti-VEGF Drugs Information
15.4.3 SWOT Analysis of Pfizer
15.4.4 Pfizer Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.5 Amgen
15.5.1 Company Profile
15.5.2 Main Business and Anti-VEGF Drugs Information
15.5.3 SWOT Analysis of Amgen
15.5.4 Amgen Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.6 Novartis
15.6.1 Company Profile
15.6.2 Main Business and Anti-VEGF Drugs Information
15.6.3 SWOT Analysis of Novartis
15.6.4 Novartis Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.7 AbbVie
15.7.1 Company Profile
15.7.2 Main Business and Anti-VEGF Drugs Information
15.7.3 SWOT Analysis of AbbVie
15.7.4 AbbVie Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.8 Samsung Bioepis
15.8.1 Company Profile
15.8.2 Main Business and Anti-VEGF Drugs Information
15.8.3 SWOT Analysis of Samsung Bioepis
15.8.4 Samsung Bioepis Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.9 Biogen Inc.
15.9.1 Company Profile
15.9.2 Main Business and Anti-VEGF Drugs Information
15.9.3 SWOT Analysis of Biogen Inc.
15.9.4 Biogen Inc. Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.10 Viatris
15.10.1 Company Profile
15.10.2 Main Business and Anti-VEGF Drugs Information
15.10.3 SWOT Analysis of Viatris
15.10.4 Viatris Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.11 Teva Pharmaceuticals
15.11.1 Company Profile
15.11.2 Main Business and Anti-VEGF Drugs Information
15.11.3 SWOT Analysis of Teva Pharmaceuticals
15.11.4 Teva Pharmaceuticals Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.12 Dr. Reddy's
15.12.1 Company Profile
15.12.2 Main Business and Anti-VEGF Drugs Information
15.12.3 SWOT Analysis of Dr. Reddy's
15.12.4 Dr. Reddy's Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.13 Xbrane Biopharma AB
15.13.1 Company Profile
15.13.2 Main Business and Anti-VEGF Drugs Information
15.13.3 SWOT Analysis of Xbrane Biopharma AB
15.13.4 Xbrane Biopharma AB Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.14 STADA Arzneimittel AG
15.14.1 Company Profile
15.14.2 Main Business and Anti-VEGF Drugs Information
15.14.3 SWOT Analysis of STADA Arzneimittel AG
15.14.4 STADA Arzneimittel AG Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.15 Formycon AG
15.15.1 Company Profile
15.15.2 Main Business and Anti-VEGF Drugs Information
15.15.3 SWOT Analysis of Formycon AG
15.15.4 Formycon AG Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.16 Bioeq AG
15.16.1 Company Profile
15.16.2 Main Business and Anti-VEGF Drugs Information
15.16.3 SWOT Analysis of Bioeq AG
15.16.4 Bioeq AG Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
Please ask for sample pages for full companies list
Chapter 1 Executive Summary
Chapter 2 Abbreviation and Acronyms
Chapter 3 Preface
3.1 Research Scope
3.2 Research Sources
3.2.1 Data Sources
3.2.2 Assumptions
3.3 Research Method
Chapter 4 Market Landscape
4.1 Market Overview
4.2 Classification/Types
4.3 Application/End Users
Chapter 5 Market Trend Analysis
5.1 introduction
5.2 Drivers
5.3 Restraints
5.4 Opportunities
5.5 Threats
Chapter 6 industry Chain Analysis
6.1 Upstream/Suppliers Analysis
6.2 Anti-VEGF Drugs Analysis
6.2.1 Technology Analysis
6.2.2 Cost Analysis
6.2.3 Market Channel Analysis
6.3 Downstream Buyers/End Users
Chapter 7 Latest Market Dynamics
7.1 Latest News
7.2 Merger and Acquisition
7.3 Planned/Future Project
7.4 Policy Dynamics
Chapter 8 Historical and Forecast Anti-VEGF Drugs Market in North America (2020-2030)
8.1 Anti-VEGF Drugs Market Size
8.2 Anti-VEGF Drugs Market by End Use
8.3 Competition by Players/Suppliers
8.4 Anti-VEGF Drugs Market Size by Type
8.5 Key Countries Analysis
8.5.1 United States
8.5.2 Canada
8.5.3 Mexico
Chapter 9 Historical and Forecast Anti-VEGF Drugs Market in South America (2020-2030)
9.1 Anti-VEGF Drugs Market Size
9.2 Anti-VEGF Drugs Market by End Use
9.3 Competition by Players/Suppliers
9.4 Anti-VEGF Drugs Market Size by Type
9.5 Key Countries Analysis
9.5.1 Brazil
9.5.2 Argentina
9.5.3 Chile
9.5.4 Peru
Chapter 10 Historical and Forecast Anti-VEGF Drugs Market in Asia & Pacific (2020-2030)
10.1 Anti-VEGF Drugs Market Size
10.2 Anti-VEGF Drugs Market by End Use
10.3 Competition by Players/Suppliers
10.4 Anti-VEGF Drugs Market Size by Type
10.5 Key Countries Analysis
10.5.1 China
10.5.2 India
10.5.3 Japan
10.5.4 South Korea
10.5.5 Southest Asia
10.5.6 Australia
Chapter 11 Historical and Forecast Anti-VEGF Drugs Market in Europe (2020-2030)
11.1 Anti-VEGF Drugs Market Size
11.2 Anti-VEGF Drugs Market by End Use
11.3 Competition by Players/Suppliers
11.4 Anti-VEGF Drugs Market Size by Type
11.5 Key Countries Analysis
11.5.1 Germany
11.5.2 France
11.5.3 United Kingdom
11.5.4 Italy
11.5.5 Spain
11.5.6 Belgium
11.5.7 Netherlands
11.5.8 Austria
11.5.9 Poland
11.5.10 Russia
Chapter 12 Historical and Forecast Anti-VEGF Drugs Market in MEA (2020-2030)
12.1 Anti-VEGF Drugs Market Size
12.2 Anti-VEGF Drugs Market by End Use
12.3 Competition by Players/Suppliers
12.4 Anti-VEGF Drugs Market Size by Type
12.5 Key Countries Analysis
12.5.1 Egypt
12.5.2 Israel
12.5.3 South Africa
12.5.4 Gulf Cooperation Council Countries
12.5.5 Turkey
Chapter 13 Summary For Global Anti-VEGF Drugs Market (2020-2025)
13.1 Anti-VEGF Drugs Market Size
13.2 Anti-VEGF Drugs Market by End Use
13.3 Competition by Players/Suppliers
13.4 Anti-VEGF Drugs Market Size by Type
Chapter 14 Global Anti-VEGF Drugs Market Forecast (2025-2030)
14.1 Anti-VEGF Drugs Market Size Forecast
14.2 Anti-VEGF Drugs Application Forecast
14.3 Competition by Players/Suppliers
14.4 Anti-VEGF Drugs Type Forecast
Chapter 15 Analysis of Global Key Vendors
15.1 Bayer
15.1.1 Company Profile
15.1.2 Main Business and Anti-VEGF Drugs Information
15.1.3 SWOT Analysis of Bayer
15.1.4 Bayer Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.2 Regeneron Pharmaceuticals
15.2.1 Company Profile
15.2.2 Main Business and Anti-VEGF Drugs Information
15.2.3 SWOT Analysis of Regeneron Pharmaceuticals
15.2.4 Regeneron Pharmaceuticals Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.3 Roche
15.3.1 Company Profile
15.3.2 Main Business and Anti-VEGF Drugs Information
15.3.3 SWOT Analysis of Roche
15.3.4 Roche Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.4 Pfizer
15.4.1 Company Profile
15.4.2 Main Business and Anti-VEGF Drugs Information
15.4.3 SWOT Analysis of Pfizer
15.4.4 Pfizer Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.5 Amgen
15.5.1 Company Profile
15.5.2 Main Business and Anti-VEGF Drugs Information
15.5.3 SWOT Analysis of Amgen
15.5.4 Amgen Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.6 Novartis
15.6.1 Company Profile
15.6.2 Main Business and Anti-VEGF Drugs Information
15.6.3 SWOT Analysis of Novartis
15.6.4 Novartis Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.7 AbbVie
15.7.1 Company Profile
15.7.2 Main Business and Anti-VEGF Drugs Information
15.7.3 SWOT Analysis of AbbVie
15.7.4 AbbVie Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.8 Samsung Bioepis
15.8.1 Company Profile
15.8.2 Main Business and Anti-VEGF Drugs Information
15.8.3 SWOT Analysis of Samsung Bioepis
15.8.4 Samsung Bioepis Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.9 Biogen Inc.
15.9.1 Company Profile
15.9.2 Main Business and Anti-VEGF Drugs Information
15.9.3 SWOT Analysis of Biogen Inc.
15.9.4 Biogen Inc. Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.10 Viatris
15.10.1 Company Profile
15.10.2 Main Business and Anti-VEGF Drugs Information
15.10.3 SWOT Analysis of Viatris
15.10.4 Viatris Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.11 Teva Pharmaceuticals
15.11.1 Company Profile
15.11.2 Main Business and Anti-VEGF Drugs Information
15.11.3 SWOT Analysis of Teva Pharmaceuticals
15.11.4 Teva Pharmaceuticals Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.12 Dr. Reddy's
15.12.1 Company Profile
15.12.2 Main Business and Anti-VEGF Drugs Information
15.12.3 SWOT Analysis of Dr. Reddy's
15.12.4 Dr. Reddy's Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.13 Xbrane Biopharma AB
15.13.1 Company Profile
15.13.2 Main Business and Anti-VEGF Drugs Information
15.13.3 SWOT Analysis of Xbrane Biopharma AB
15.13.4 Xbrane Biopharma AB Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.14 STADA Arzneimittel AG
15.14.1 Company Profile
15.14.2 Main Business and Anti-VEGF Drugs Information
15.14.3 SWOT Analysis of STADA Arzneimittel AG
15.14.4 STADA Arzneimittel AG Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.15 Formycon AG
15.15.1 Company Profile
15.15.2 Main Business and Anti-VEGF Drugs Information
15.15.3 SWOT Analysis of Formycon AG
15.15.4 Formycon AG Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
15.16 Bioeq AG
15.16.1 Company Profile
15.16.2 Main Business and Anti-VEGF Drugs Information
15.16.3 SWOT Analysis of Bioeq AG
15.16.4 Bioeq AG Anti-VEGF Drugs Sales, Revenue, Price and Gross Margin (2020-2025)
Please ask for sample pages for full companies list
Table Abbreviation and Acronyms
Table Research Scope of Anti-VEGF Drugs Report
Table Data Sources of Anti-VEGF Drugs Report
Table Major Assumptions of Anti-VEGF Drugs Report
Table Anti-VEGF Drugs Classification
Table Anti-VEGF Drugs Applications
Table Drivers of Anti-VEGF Drugs Market
Table Restraints of Anti-VEGF Drugs Market
Table Opportunities of Anti-VEGF Drugs Market
Table Threats of Anti-VEGF Drugs Market
Table Raw Materials Suppliers
Table Different Production Methods of Anti-VEGF Drugs
Table Cost Structure Analysis of Anti-VEGF Drugs
Table Key End Users
Table Latest News of Anti-VEGF Drugs Market
Table Merger and Acquisition
Table Planned/Future Project of Anti-VEGF Drugs Market
Table Policy of Anti-VEGF Drugs Market
Table 2020-2030 North America Anti-VEGF Drugs Market Size
Table 2020-2030 North America Anti-VEGF Drugs Market Size by Application
Table 2020-2025 North America Anti-VEGF Drugs Key Players Revenue
Table 2020-2025 North America Anti-VEGF Drugs Key Players Market Share
Table 2020-2030 North America Anti-VEGF Drugs Market Size by Type
Table 2020-2030 United States Anti-VEGF Drugs Market Size
Table 2020-2030 Canada Anti-VEGF Drugs Market Size
Table 2020-2030 Mexico Anti-VEGF Drugs Market Size
Table 2020-2030 South America Anti-VEGF Drugs Market Size
Table 2020-2030 South America Anti-VEGF Drugs Market Size by Application
Table 2020-2025 South America Anti-VEGF Drugs Key Players Revenue
Table 2020-2025 South America Anti-VEGF Drugs Key Players Market Share
Table 2020-2030 South America Anti-VEGF Drugs Market Size by Type
Table 2020-2030 Brazil Anti-VEGF Drugs Market Size
Table 2020-2030 Argentina Anti-VEGF Drugs Market Size
Table 2020-2030 Chile Anti-VEGF Drugs Market Size
Table 2020-2030 Peru Anti-VEGF Drugs Market Size
Table 2020-2030 Asia & Pacific Anti-VEGF Drugs Market Size
Table 2020-2030 Asia & Pacific Anti-VEGF Drugs Market Size by Application
Table 2020-2025 Asia & Pacific Anti-VEGF Drugs Key Players Revenue
Table 2020-2025 Asia & Pacific Anti-VEGF Drugs Key Players Market Share
Table 2020-2030 Asia & Pacific Anti-VEGF Drugs Market Size by Type
Table 2020-2030 China Anti-VEGF Drugs Market Size
Table 2020-2030 India Anti-VEGF Drugs Market Size
Table 2020-2030 Japan Anti-VEGF Drugs Market Size
Table 2020-2030 South Korea Anti-VEGF Drugs Market Size
Table 2020-2030 Southeast Asia Anti-VEGF Drugs Market Size
Table 2020-2030 Australia Anti-VEGF Drugs Market Size
Table 2020-2030 Europe Anti-VEGF Drugs Market Size
Table 2020-2030 Europe Anti-VEGF Drugs Market Size by Application
Table 2020-2025 Europe Anti-VEGF Drugs Key Players Revenue
Table 2020-2025 Europe Anti-VEGF Drugs Key Players Market Share
Table 2020-2030 Europe Anti-VEGF Drugs Market Size by Type
Table 2020-2030 Germany Anti-VEGF Drugs Market Size
Table 2020-2030 France Anti-VEGF Drugs Market Size
Table 2020-2030 United Kingdom Anti-VEGF Drugs Market Size
Table 2020-2030 Italy Anti-VEGF Drugs Market Size
Table 2020-2030 Spain Anti-VEGF Drugs Market Size
Table 2020-2030 Belgium Anti-VEGF Drugs Market Size
Table 2020-2030 Netherlands Anti-VEGF Drugs Market Size
Table 2020-2030 Austria Anti-VEGF Drugs Market Size
Table 2020-2030 Poland Anti-VEGF Drugs Market Size
Table 2020-2030 Russia Anti-VEGF Drugs Market Size
Table 2020-2030 MEA Anti-VEGF Drugs Market Size
Table 2020-2030 MEA Anti-VEGF Drugs Market Size by Application
Table 2020-2025 MEA Anti-VEGF Drugs Key Players Revenue
Table 2020-2025 MEA Anti-VEGF Drugs Key Players Market Share
Table 2020-2030 MEA Anti-VEGF Drugs Market Size by Type
Table 2020-2030 Egypt Anti-VEGF Drugs Market Size
Table 2020-2030 Israel Anti-VEGF Drugs Market Size
Table 2020-2030 South Africa Anti-VEGF Drugs Market Size
Table 2020-2030 Gulf Cooperation Council Countries Anti-VEGF Drugs Market Size
Table 2020-2030 Turkey Anti-VEGF Drugs Market Size
Table 2020-2025 Global Anti-VEGF Drugs Market Size by Region
Table 2020-2025 Global Anti-VEGF Drugs Market Size Share by Region
Table 2020-2025 Global Anti-VEGF Drugs Market Size by Application
Table 2020-2025 Global Anti-VEGF Drugs Market Share by Application
Table 2020-2025 Global Anti-VEGF Drugs Key Vendors Revenue
Table 2020-2025 Global Anti-VEGF Drugs Key Vendors Market Share
Table 2020-2025 Global Anti-VEGF Drugs Market Size by Type
Table 2020-2025 Global Anti-VEGF Drugs Market Share by Type
Table 2025-2030 Global Anti-VEGF Drugs Market Size by Region
Table 2025-2030 Global Anti-VEGF Drugs Market Size Share by Region
Table 2025-2030 Global Anti-VEGF Drugs Market Size by Application
Table 2025-2030 Global Anti-VEGF Drugs Market Share by Application
Table 2025-2030 Global Anti-VEGF Drugs Key Vendors Revenue
Table 2025-2030 Global Anti-VEGF Drugs Key Vendors Market Share
Table 2025-2030 Global Anti-VEGF Drugs Market Size by Type
Table 2025-2030 Anti-VEGF Drugs Global Market Share by Type
Figure Market Size Estimated Method
Figure Major Forecasting Factors
Figure Anti-VEGF Drugs Picture
Figure 2020-2030 North America Anti-VEGF Drugs Market Size and CAGR
Figure 2020-2030 South America Anti-VEGF Drugs Market Size and CAGR
Figure 2020-2030 Asia & Pacific Anti-VEGF Drugs Market Size and CAGR
Figure 2020-2030 Europe Anti-VEGF Drugs Market Size and CAGR
Figure 2020-2030 MEA Anti-VEGF Drugs Market Size and CAGR
Figure 2020-2025 Global Anti-VEGF Drugs Market Size and Growth Rate
Figure 2025-2030 Global Anti-VEGF Drugs Market Size and Growth Rate
Table Research Scope of Anti-VEGF Drugs Report
Table Data Sources of Anti-VEGF Drugs Report
Table Major Assumptions of Anti-VEGF Drugs Report
Table Anti-VEGF Drugs Classification
Table Anti-VEGF Drugs Applications
Table Drivers of Anti-VEGF Drugs Market
Table Restraints of Anti-VEGF Drugs Market
Table Opportunities of Anti-VEGF Drugs Market
Table Threats of Anti-VEGF Drugs Market
Table Raw Materials Suppliers
Table Different Production Methods of Anti-VEGF Drugs
Table Cost Structure Analysis of Anti-VEGF Drugs
Table Key End Users
Table Latest News of Anti-VEGF Drugs Market
Table Merger and Acquisition
Table Planned/Future Project of Anti-VEGF Drugs Market
Table Policy of Anti-VEGF Drugs Market
Table 2020-2030 North America Anti-VEGF Drugs Market Size
Table 2020-2030 North America Anti-VEGF Drugs Market Size by Application
Table 2020-2025 North America Anti-VEGF Drugs Key Players Revenue
Table 2020-2025 North America Anti-VEGF Drugs Key Players Market Share
Table 2020-2030 North America Anti-VEGF Drugs Market Size by Type
Table 2020-2030 United States Anti-VEGF Drugs Market Size
Table 2020-2030 Canada Anti-VEGF Drugs Market Size
Table 2020-2030 Mexico Anti-VEGF Drugs Market Size
Table 2020-2030 South America Anti-VEGF Drugs Market Size
Table 2020-2030 South America Anti-VEGF Drugs Market Size by Application
Table 2020-2025 South America Anti-VEGF Drugs Key Players Revenue
Table 2020-2025 South America Anti-VEGF Drugs Key Players Market Share
Table 2020-2030 South America Anti-VEGF Drugs Market Size by Type
Table 2020-2030 Brazil Anti-VEGF Drugs Market Size
Table 2020-2030 Argentina Anti-VEGF Drugs Market Size
Table 2020-2030 Chile Anti-VEGF Drugs Market Size
Table 2020-2030 Peru Anti-VEGF Drugs Market Size
Table 2020-2030 Asia & Pacific Anti-VEGF Drugs Market Size
Table 2020-2030 Asia & Pacific Anti-VEGF Drugs Market Size by Application
Table 2020-2025 Asia & Pacific Anti-VEGF Drugs Key Players Revenue
Table 2020-2025 Asia & Pacific Anti-VEGF Drugs Key Players Market Share
Table 2020-2030 Asia & Pacific Anti-VEGF Drugs Market Size by Type
Table 2020-2030 China Anti-VEGF Drugs Market Size
Table 2020-2030 India Anti-VEGF Drugs Market Size
Table 2020-2030 Japan Anti-VEGF Drugs Market Size
Table 2020-2030 South Korea Anti-VEGF Drugs Market Size
Table 2020-2030 Southeast Asia Anti-VEGF Drugs Market Size
Table 2020-2030 Australia Anti-VEGF Drugs Market Size
Table 2020-2030 Europe Anti-VEGF Drugs Market Size
Table 2020-2030 Europe Anti-VEGF Drugs Market Size by Application
Table 2020-2025 Europe Anti-VEGF Drugs Key Players Revenue
Table 2020-2025 Europe Anti-VEGF Drugs Key Players Market Share
Table 2020-2030 Europe Anti-VEGF Drugs Market Size by Type
Table 2020-2030 Germany Anti-VEGF Drugs Market Size
Table 2020-2030 France Anti-VEGF Drugs Market Size
Table 2020-2030 United Kingdom Anti-VEGF Drugs Market Size
Table 2020-2030 Italy Anti-VEGF Drugs Market Size
Table 2020-2030 Spain Anti-VEGF Drugs Market Size
Table 2020-2030 Belgium Anti-VEGF Drugs Market Size
Table 2020-2030 Netherlands Anti-VEGF Drugs Market Size
Table 2020-2030 Austria Anti-VEGF Drugs Market Size
Table 2020-2030 Poland Anti-VEGF Drugs Market Size
Table 2020-2030 Russia Anti-VEGF Drugs Market Size
Table 2020-2030 MEA Anti-VEGF Drugs Market Size
Table 2020-2030 MEA Anti-VEGF Drugs Market Size by Application
Table 2020-2025 MEA Anti-VEGF Drugs Key Players Revenue
Table 2020-2025 MEA Anti-VEGF Drugs Key Players Market Share
Table 2020-2030 MEA Anti-VEGF Drugs Market Size by Type
Table 2020-2030 Egypt Anti-VEGF Drugs Market Size
Table 2020-2030 Israel Anti-VEGF Drugs Market Size
Table 2020-2030 South Africa Anti-VEGF Drugs Market Size
Table 2020-2030 Gulf Cooperation Council Countries Anti-VEGF Drugs Market Size
Table 2020-2030 Turkey Anti-VEGF Drugs Market Size
Table 2020-2025 Global Anti-VEGF Drugs Market Size by Region
Table 2020-2025 Global Anti-VEGF Drugs Market Size Share by Region
Table 2020-2025 Global Anti-VEGF Drugs Market Size by Application
Table 2020-2025 Global Anti-VEGF Drugs Market Share by Application
Table 2020-2025 Global Anti-VEGF Drugs Key Vendors Revenue
Table 2020-2025 Global Anti-VEGF Drugs Key Vendors Market Share
Table 2020-2025 Global Anti-VEGF Drugs Market Size by Type
Table 2020-2025 Global Anti-VEGF Drugs Market Share by Type
Table 2025-2030 Global Anti-VEGF Drugs Market Size by Region
Table 2025-2030 Global Anti-VEGF Drugs Market Size Share by Region
Table 2025-2030 Global Anti-VEGF Drugs Market Size by Application
Table 2025-2030 Global Anti-VEGF Drugs Market Share by Application
Table 2025-2030 Global Anti-VEGF Drugs Key Vendors Revenue
Table 2025-2030 Global Anti-VEGF Drugs Key Vendors Market Share
Table 2025-2030 Global Anti-VEGF Drugs Market Size by Type
Table 2025-2030 Anti-VEGF Drugs Global Market Share by Type
Figure Market Size Estimated Method
Figure Major Forecasting Factors
Figure Anti-VEGF Drugs Picture
Figure 2020-2030 North America Anti-VEGF Drugs Market Size and CAGR
Figure 2020-2030 South America Anti-VEGF Drugs Market Size and CAGR
Figure 2020-2030 Asia & Pacific Anti-VEGF Drugs Market Size and CAGR
Figure 2020-2030 Europe Anti-VEGF Drugs Market Size and CAGR
Figure 2020-2030 MEA Anti-VEGF Drugs Market Size and CAGR
Figure 2020-2025 Global Anti-VEGF Drugs Market Size and Growth Rate
Figure 2025-2030 Global Anti-VEGF Drugs Market Size and Growth Rate
Research Methodology
- Market Estimated Methodology:
Bottom-up & top-down approach, supply & demand approach are the most important method which is used by HDIN Research to estimate the market size.
1）Top-down & Bottom-up Approach
Top-down approach uses a general market size figure and determines the percentage that the objective market represents.
Bottom-up approach size the objective market by collecting the sub-segment information.
2）Supply & Demand Approach
Supply approach is based on assessments of the size of each competitor supplying the objective market.
Demand approach combine end-user data within a market to estimate the objective market size. It is sometimes referred to as bottom-up approach.
- Forecasting Methodology
- Numerous factors impacting the market trend are considered for forecast model:
- New technology and application in the future;
- New project planned/under contraction;
- Global and regional underlying economic growth;
- Threatens of substitute products;
- Industry expert opinion;
- Policy and Society implication.
- Analysis Tools
1）PEST Analysis
PEST Analysis is a simple and widely used tool that helps our client analyze the Political, Economic, Socio-Cultural, and Technological changes in their business environment.
- Benefits of a PEST analysis:
- It helps you to spot business opportunities, and it gives you advanced warning of significant threats.
- It reveals the direction of change within your business environment. This helps you shape what you’re doing, so that you work with change, rather than against it.
- It helps you avoid starting projects that are likely to fail, for reasons beyond your control.
- It can help you break free of unconscious assumptions when you enter a new country, region, or market; because it helps you develop an objective view of this new environment.
2）Porter’s Five Force Model Analysis
The Porter’s Five Force Model is a tool that can be used to analyze the opportunities and overall competitive advantage. The five forces that can assist in determining the competitive intensity and potential attractiveness within a specific area.
- Threat of New Entrants: Profitable industries that yield high returns will attract new firms.
- Threat of Substitutes: A substitute product uses a different technology to try to solve the same economic need.
- Bargaining Power of Customers: the ability of customers to put the firm under pressure, which also affects the customer's sensitivity to price changes.
- Bargaining Power of Suppliers: Suppliers of raw materials, components, labor, and services (such as expertise) to the firm can be a source of power over the firm when there are few substitutes.
- Competitive Rivalry: For most industries the intensity of competitive rivalry is the major determinant of the competitiveness of the industry.
3）Value Chain Analysis
Value chain analysis is a tool to identify activities, within and around the firm and relating these activities to an assessment of competitive strength. Value chain can be analyzed by primary activities and supportive activities. Primary activities include: inbound logistics, operations, outbound logistics, marketing & sales, service. Support activities include: technology development, human resource management, management, finance, legal, planning.
4）SWOT Analysis
SWOT analysis is a tool used to evaluate a company's competitive position by identifying its strengths, weaknesses, opportunities and threats. The strengths and weakness is the inner factor; the opportunities and threats are the external factor. By analyzing the inner and external factors, the analysis can provide the detail information of the position of a player and the characteristics of the industry.
- Strengths describe what the player excels at and separates it from the competition
- Weaknesses stop the player from performing at its optimum level.
- Opportunities refer to favorable external factors that the player can use to give it a competitive advantage.
- Threats refer to factors that have the potential to harm the player.
- Data Sources
| Primary Sources | Secondary Sources |
|---|---|
| Face to face/Phone Interviews with market participants, such as: Manufactures; Distributors; End-users; Experts. Online Survey |
Government/International Organization Data: Annual Report/Presentation/Fact Book Internet Source Information Industry Association Data Free/Purchased Database Market Research Report Book/Journal/News |